Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. [electronic resource]
Producer: 20080306Description: 179-85 p. digitalISSN:- 1476-5551
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Blotting, Western
- Boronic Acids -- administration & dosage
- Bortezomib
- Caspases -- metabolism
- Cell Proliferation
- Cyclophosphamide -- administration & dosage
- Drug Synergism
- Immunophenotyping
- In Vitro Techniques
- Lymphoma, Mantle-Cell -- drug therapy
- Male
- Mice
- Mice, SCID
- Poly(ADP-ribose) Polymerases -- metabolism
- Pyrazines -- administration & dosage
- Rituximab
- Survival Rate
- Transplantation, Heterologous
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.